Engineered TrpB Enzyme for Stereoselective Beta-Branched Tryptophan Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The synthesis of β-branched non-canonical amino acids (ncAAs) is hindered by the challenge of forming two adjacent stereocenters while tolerating reactive functional groups, leading to inefficient and multi-step processes with low stereoselectivity, limiting their availability for bioactive molecules and therapeutics.
Innovation Solution
The use of an engineered variant of Pyrococcus furiosus tryptophan synthase (PfTrpB), PfTrpB7E6, which undergoes directed evolution to promote the formation and persistence of a key amino-acrylate intermediate, enabling the stereoselective biocatalytic synthesis of β-branched tryptophan analogs with improved yields and coupling efficiencies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional organic synthesis methods are used to synthesize β-branched non-canonical amino acids, then the synthesis can be performed with conventional reagents and catalysts, but the process requires multiple steps with protecting groups, hazardous reagents, and expensive metal catalysts, resulting in low efficiency and poor stereoselectivity
Solution Approach 1:
The patent replaces traditional mechanical/chemical synthesis methods with biocatalysis using engineered tryptophan synthase β-subunit (TrpB). The enzyme catalyzes the formation of β-branched non-canonical amino acids from indole and β-substituted serine in a single step, eliminating the need for multiple protection/deprotection steps, hazardous reagents, and expensive metal catalysts. This substitution of chemical synthesis with enzymatic catalysis directly resolves the contradiction by improving productivity while reducing process complexity.
Solution Approach 2:
The patent employs directed evolution to optimize the TrpB enzyme parameters, specifically introducing amino acid mutations (e.g., L161A, L161V) that enhance the enzyme's ability to form and stabilize the amino-acrylate intermediate. These parameter changes in the enzyme's catalytic mechanism enable high stereoselectivity and efficiency in a single step, transforming the synthesis from a multi-step low-yield process to a streamlined high-yield reaction.
2Manufacturing precision
If traditional organic synthesis methods are used, then conventional reagents can be employed, but the formation of two adjacent stereocenters is challenging, leading to low stereoselectivity and the need for protecting groups
Solution Approach 1:
The patent replaces conventional chemical synthesis with enzymatic catalysis using engineered TrpB, which inherently provides high stereoselectivity through its chiral active site. The enzyme naturally forms two adjacent stereocenters with precise stereocontrol during the condensation of indole and β-substituted serine, eliminating the need for protecting groups and multiple steps required in traditional methods to achieve similar stereoselectivity.
Solution Approach 2:
The patent introduces specific amino acid mutations in TrpB (such as L161A, L161V) that modify the enzyme's active site parameters to better accommodate substrates with various β-substituents. These parameter changes enhance the enzyme's ability to maintain high stereoselectivity while tolerating diverse functional groups, thereby improving ease of manufacture for different β-branched amino acid variants.
3Reliability
If multi-step synthesis with protecting groups is used, then the reactive functional groups can be managed, but the process becomes inefficient and requires hazardous reagents and expensive metal catalysts
Solution Approach 1:
The patent substitutes chemical synthesis with biocatalytic synthesis using engineered TrpB, which provides inherent tolerance to reactive functional groups through its enzymatic mechanism. The enzyme's active site is designed to accommodate various β-substituted serines with different functional groups (halogens, hydroxyls, nitriles, etc.) without requiring protection, while maintaining high catalytic efficiency. This eliminates the need for protecting groups and hazardous reagents, resolving the contradiction between reliability and productivity.
4Adaptability or versatility
If conventional synthesis methods are employed, then standard chemical processes can be used, but the availability of β-branched non-canonical amino acids is limited due to the challenge of forming two adjacent stereocenters
Solution Approach 1:
The patent uses directed evolution to optimize TrpB enzyme parameters, introducing mutations that expand the enzyme's substrate scope to accommodate various indoles and β-substituted serines with different functional groups. The engineered enzyme maintains high stereoselectivity and efficiency across diverse substrates, including 27 previously unreported compounds. This parameter optimization enables broad adaptability while ensuring ease of manufacture through a single-step enzymatic process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a simple and environmentally benign method for producing enantiopure β-branched tryptophan analogs, including 27 previously unreported compounds, with enhanced yields and substrate scope, addressing the limitations of traditional synthesis methods.
Implementation Method 1
combining i) an unsubstituted indole or a substituted indole, ii) a β-substituted serine, and iii) a tryptophan synthase β-subunit (i.e., a TrpB) comprising the amino acid sequence set forth in SEQ ID NO: 1 and further comprising at least one amino acid mutation, wherein the amino acid mutation promotes formation of an amino-acrylate intermediate
Data Source
AI summary
The present disclosure provides methods for preparing β-substituted tryptophan compounds. The methods include: combining i) an unsubstituted indole or a substituted indole, ii) a β-substituted serine, and iii) a tryptophan synthase β-subunit (i.e., a TrpB); and maintaining the resulting mixture under conditions sufficient to form the β-substituted tryptophan. The TrpB contains at least one amino acid mutation which promotes formation of an amino-acrylate intermediate. New TrpB variants and new β-substituted tryptophan analogs are also described.